Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.15125Keywords:
biomarkers, hepatocellular carcinoma, prognosisAbstract
Summary. Background: Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC. Aim: We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis and diagnosis of patients with HCC. Materials and Methods: 60 HCC patients (75% male) and 20 healthy volunteers (70% male) were enrolled in this prospective study. Serum samples were obtained during the first admission before any adjuvant or metastatic treatments were administered. Serum biomarkers were determined using ELISA kits. Results: All patients had cirrhosis, and the Child — Pugh stages were as follows: 61.5% Child — Pugh A, 35.9% Child — Pugh B and 2.6% Child — Pugh C (61.7% hepatitis B virus, 11.7% hepatitis C virus, 6.7% hepatitis B virus + hepatitis C virus, 11.7% alcoholic and 8.3% cryptogenic). Fifty-three percent of the HCC patients died within a median of 7.5 months. The mean serum level of IL-29 in patients with HCC was higher than that in the control group (32.55 pg/ml vs 11.46 pg/ml, p < 0.015). Galectin-3 levels were significantly higher in the HCC group (6.7 ng/ml vs 1.38 ng/ml, p < 0.001). Fibronectin levels were higher in the control group than in the HCC group (260 635 ng/ml vs 257 353 ng/ml). However, the mean protease-activated receptor-1 and leptin levels were similar between the two groups (p > 0.05). The biomarkers were divided into two groups according to their median level. In the log rank analysis, biomarkers had no effect on survival (p > 0.05). Conclusions: IL-29 and galectin-3 levels were significantly higher in HCC patients. Although IL-29 and galectin-3 can be used as diagnostic markers for HCC, they had no prognostic value in HCC patients.
References
Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol 2017; 23: 5282–94.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358–80.
Balogh J, Victor D, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016; 3: 41–53.
European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol 2014; 28: 843–53.
Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-Fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicentre study. PLoS One 2016; 11: e0153227.
Lou J, Zhang L, Lv S, et al. Biomarkers for hepatocellular carcinoma. Biomark Cancer 2017; 9: 1–9.
Chen ZY, Wei W, Guo ZX, et al. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer 2014; 110: 733–40.
Uze G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007; 89: 729–34.
Cao Y, Zhang R, Zhang W, et al. IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol 2014; 192: 691–703.
Yu Y, Gong R, Mu Y, et al. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J Immunol 2011; 187: 4844–60.
Naumnik W, Naumnik B, Niewiarowska K, et al. Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Exp Oncol 2012; 34: 348–53.
Witte K, Witte E, Sabat R, et al. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 21: 237–51.
Jiang SS, Weng DS, Wang QJ, et al. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med 2014; 12: 273.
Hsu DK, Dowling CA, Jeng KC, et al. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999; 81: 519–26.
Jiang N, Sun R, Sun Q. Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Des Devel Ther 2014; 8: 2295–302.
Shen J, Yeh CC, Wang Q, et al. Plasma adiponectin and hepatocellular carcinoma survival among patients without liver transplantation. Anticancer Res 2016; 36: 5307–14.
Lynagh GR, Collins RA, Kaiser P. Development and use of monoclonal antibodies to chicken fibronectin to show that the chicken hepatocellular carcinoma cell line, LMH, constitutively expresses fibronectin. Res Vet Sci 2000; 68: 147–52.
Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006; 118: 1331–9.
Gupta N, Kakkar N, Vasishta RK. Pattern of fibronectin in hepatocellular carcinoma and its significance. Indian J Pathol Microbiol 2006; 49: 362–4.
Mussbach F, Henklein P, Westermann M, et al. Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation. J Cancer Res Clin Oncol 2015; 141: 813–25.
Scaggiante B, Kazemi M, Pozzato G, et al. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol 2014; 20: 1268–88.
Fujie H, Tanaka T, Tagawa M, et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011; 102: 1977–90.
Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol 2010; 16: 5801–9.
Andrighetto LV, Poziomyck AK. Serum leptin levens and hepatocellular carcinoma: review article. Arq Bras Cir Dig 2016; 29: 276–8.
Sadik NA, Ahmed A, Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol 2012; 31: 311–21.
Moriya K, Sakai K, Yan MH, Sakai T. Fibronectin is essential for survival but is dispensable for proliferation of hepatocytes in acute liver injury in mice. Hepatology 2012; 56: 311–21.
Tamkun JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 1983; 258: 4641–7.
Kim H, Park J, Kim Y, et al. Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. Sci Rep 2017; 7: 9449.
Han N, Jin K, He K, et al. Protease-activated receptors in cancer: a systematic review. Oncol Lett 2011; 2: 599–608.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
